"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 5 | 2 | 7 |
| 1996 | 13 | 2 | 15 |
| 1997 | 8 | 1 | 9 |
| 1998 | 22 | 5 | 27 |
| 1999 | 9 | 9 | 18 |
| 2000 | 16 | 6 | 22 |
| 2001 | 23 | 6 | 29 |
| 2002 | 36 | 11 | 47 |
| 2003 | 30 | 11 | 41 |
| 2004 | 37 | 13 | 50 |
| 2005 | 31 | 19 | 50 |
| 2006 | 35 | 20 | 55 |
| 2007 | 44 | 16 | 60 |
| 2008 | 33 | 18 | 51 |
| 2009 | 40 | 24 | 64 |
| 2010 | 53 | 28 | 81 |
| 2011 | 63 | 18 | 81 |
| 2012 | 56 | 26 | 82 |
| 2013 | 54 | 23 | 77 |
| 2014 | 70 | 23 | 93 |
| 2015 | 82 | 33 | 115 |
| 2016 | 59 | 29 | 88 |
| 2017 | 56 | 28 | 84 |
| 2018 | 43 | 25 | 68 |
| 2019 | 42 | 23 | 65 |
| 2020 | 34 | 18 | 52 |
| 2021 | 42 | 16 | 58 |
| 2022 | 20 | 2 | 22 |
| 2023 | 41 | 0 | 41 |
| 2024 | 11 | 23 | 34 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC). J Med Chem. 2025 Feb 27; 68(4):4961-4987.
-
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro Oncol. 2024 Dec 05; 26(12):2316-2327.
-
Nanoscale Mixed-Ligand Metal-Organic Framework for X-ray Stimulated Cancer Therapy. J Am Chem Soc. 2024 Dec 04; 146(48):33149-33158.
-
Exploring the potential of TGFß as a diagnostic marker and therapeutic target against cancer. Biochem Pharmacol. 2025 Jan; 231:116646.
-
Bifunctional Metal-Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio-Immunotherapy. Angew Chem Int Ed Engl. 2025 Jan 27; 64(5):e202417027.
-
Multifunctional Nanomaterials Mediate Cholesterol Depletion for Cancer Treatment. Angew Chem Int Ed Engl. 2024 Nov 11; 63(46):e202412844.
-
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.
-
Enhancing carboplatin sensitivity in ovarian cancer cells by blocking the mercapturic acid pathway transporter. Carcinogenesis. 2024 Sep 11; 45(9):696-707.
-
Direct inhibition of tumor hypoxia response with synthetic transcriptional repressors. Nat Chem Biol. 2025 Feb; 21(2):247-255.
-
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22; 391(8):710-721.